The city of San Antonio, Texas, currently has 64 active clinical trials seeking participants for Breast Cancer research studies.
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Recruiting
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: UT Health San Antonio - MD Anderson Cancer Center, San Antonio, Texas
Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Texas Oncology, PA - Metropolitan, San Antonio, Texas +4 locations
Conditions: Breast Cancer
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Recruiting
The goal of this phase 1/2 clinical trial is to investigate the safety of an investigational drug called VIO-01 when taken by people who have different types of solid tumor cancers. There are two parts to this trial, part 1 and part 2. Part 1 of the trial aims to answer these questions: The safety and tolerability of VIO-01 when it is given alone or in combination with other anti-cancer therapies. The highest dose that people can take without having unacceptable side effects How well your body... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Next Oncology, San Antonio, Texas
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: University Hospital, San Antonio, Texas +1 locations
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7